Breakthrough of solid tumor treatment: CAR-NK immunotherapy, review by Hung Trinh
Hung Trinh, Senior Director of Business Development at OBiO Tech, shared an article by Wenkang Wang on LinkedIn:
“Review: Breakthrough of solid tumor treatment: CAR-NK immunotherapy, however remain unclear mechanism and mode of action.
As the latest and most anticipated method of tumor immunotherapy, CAR-NK therapy has received increasing attention in recent years, and its safety and high efficiency have irreplaceable advantages over CAR-T. Current research focuses on the application of CAR-NK in hematological tumors, while there are fewer studies on solid tumor.
This article reviews the process of constructing CAR-NK, the effects of hypoxia and metabolic factors, NK cell surface receptors, cytokines, and exosomes on the efficacy of CAR-NK in solid tumor, and the role of CAR-NK in various solid tumor.
The mechanism of action and the research status of the potential of CAR-NK in the treatment of solid tumor in clinical practice, and put forward the advantages, limitations and future problems of CAR-NK in the treatment of solid tumor.
The clinical application of CAR-NK against solid tumors is largely influenced by TME. Hypoxia, acidic environment, high adenosine environment, NK cell surface receptors, TGF-β, IL, and exosomes all affect the anti-tumor activity of CAR-NK.
It can inhibit tumor cell immune escape by modifying the intrinsic pathway, combating tumor heterogeneity, antagonizing inhibitory TME, and improving the ability of CAR-NK cells to infiltrate tumor tissue.
Despite ongoing clinical trials, there remains a limited understanding of the mechanisms underlying CAR-NK efficacy in solid tumors, particularly in liver cancer, cholangiocarcinoma, and urological tumors. While some trials are underway, many are in the preliminary stage with small sample sizes, and limitations are relatively large.
The true clinical application of CAR-NK therapy requires in-depth research and experimentation.”
Breakthrough of solid tumor treatment: CAR-NK immunotherapy.
Authors: Wenkang Wang, et al.
Hung Trinh is the Senior Director of Business Development at OBiO Tech. He previously served as Director of Process Development and Manufacturing Science and Technology at Vyriad and Associate Director of Downstream Process Development at Genezen. With experience in vaccine development, spanning both pre-clinical and clinical studies, Trinh has worked with various CDMOs focusing on lentiviral vector production and CAR-T cell manufacturing.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023